secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2026-05-04T23:59:59+00:00
Accession:  0001193125-26-204161
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics updates VMT-α-NET Ph1/2a data and preliminary cash position
--------------------------------------------------------------------------------

- Preliminary cash & short-term investments as of Mar 31, 2026 disclosed; unaudited, subject to final adjustments.
- VMT-α-NET Phase 1/2a data show durable disease control across all doses; responses deepen over time.
- Company says profile supports potential registration study at current dose level.
- Manufacturing update: daily production at regional sites for ready-to-administer 212Pb products.
- Expanding pipeline includes CCK2R81 targeting and other solid tumor programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000119312526204161/0001193125-26-204161-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000119312526204161/catx-20260504.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-204161

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer